While each project we undertake with our partners is unique, we have already deployed our analytic expertise and the breadth of data contained in BioVU® in a number of different ways. In addition to the offerings and examples listed below, we are also open to exploring new ways to leverage BioVU® to improve human health – please contact us at email@example.com to discuss further.
Nashville Biosciences’ scientists have combined pheWAS™ with a wide range of other data resources to guide pharmaceutical R&D in multiple different settings, including early stage target assessment, portfolio prioritization, mid-stage indication expansion, repositioning of drugs that failed clinical trial and generic repurposing.
Nashville Biosciences’ scientists have used the clinical and genetic data in BioVU® to retrospectively analyze a wide range of patients cohorts for pharmaceutical and diagnostics clients, including patients with the same disease, patients taking the same medication or patients with the same genotype, or to generate new data through BioVU®’s capabilities to collect blood plasma samples.
A top twenty pharmaceutical company was looking to prioritize 23 early stage targets, including both internal and partnered programs. The goal was to utilize pheWAS™ and BioVU® to identify disease phenotypes that represented possible indications, and prioritize them based on the strength of evidence and fit with the company’s focus areas.
Nashville Biosciences identified 17 targets with existing SNP genotype data and scored associated disease phenotypes for each target by pheWAS™ stats, biological plausibility, market attractiveness and competitive intensity.
The Nashville Biosciences team rapidly identified validating and novel disease hypotheses for all targets and ranked the targets into three priority categories based on aggregate scoring. Upon a thorough understanding of the client’s therapeutic focus areas, we selected 4 targets for further deep dive review.
Initial promising hypotheses for novel target – disease links were identified via pheWAS™. The Nashville Biosciences team conducted deep dives into all available clinical & scientific evidence to assess these hypotheses before our client moved to in vitro biological testing.
Nashville Biosciences selected and chart reviewed cohorts of patients identified via pheWAS™ to refine the disease diagnosis and specify clinical features of the patient cohort. We then used an extensive review of published literature and other databases to build a mechanistic hypothesis and designed experiments to test it.
Nashville Biosciences is currently working through target-disease deep dives for several early clients. This approach has been used by Vanderbilt colleagues to assess 10+ target-disease concepts now in various stages of experimental testing at Vanderbilt University.
A top ten pharmaceutical company was looking to develop a novel therapy for poorly diagnosed and treated diseases. Our objective was to use electronic medical records (EMR) to identify disease and disease-protected cohorts with common static and longitudinal risk factors for sequencing and new variant identification.
Nashville Biosciences partnered with the client to developed EMR mining logic to assess project feasibility. From there, we worked to identify and validate patients for both cohorts (i.e., based on structured EMR data and de-identified chart review).
While this project is currently in progress, the feasibility assessment is complete, and we are working on cohort identification & validation. The use of retrospective data (i.e., for long-term longitudinal variables) and banked DNA samples greatly reduces total study time.